TY - JOUR
T1 - Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination
AU - Underwood, Alexander P.
AU - Sølund, Christina
AU - Fernandez-Antunez, Carlota
AU - Villadsen, Signe Lysemose
AU - Mikkelsen, Lotte S.
AU - Fahnøe, Ulrik
AU - Bollerup, Signe
AU - Winckelmann, Anni Assing
AU - Schneider, Uffe Vest
AU - Binderup, Alekxander
AU - Vizgirda, Greta
AU - Sørensen, Anna Louise
AU - Vinten, Caroline Nørløv
AU - Dalegaard, Magnus Illum
AU - Ramirez, Santseharay
AU - Weis, Nina
AU - Bukh, Jens
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023
Y1 - 2023
N2 - Background: Given the importance of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the prevention of severe coronavirus disease 2019 (COVID-19), detailed long-term analyses of neutralising antibody responses are required to inform immunisation strategies. Methods: In this study, longitudinal neutralising antibody titres to an ancestral SARS-CoV-2 isolate and cross-neutralisation to delta and omicron isolates were analysed in individuals previously infected with SARS-CoV-2, vaccinated against COVID-19, or a complex mix thereof with up to two years of follow-up. Findings: Both infection-induced and vaccine-induced neutralising responses against SARS-CoV-2 appeared to follow similar decay patterns. Following vaccination in previously infected individuals, neutralising antibody responses were more durable than prior to vaccination. Further, this study shows that vaccination after infection, as well as booster vaccination, increases the cross-neutralising potential to both delta and omicron SARS-CoV-2 variants. Interpretation: Taken together, these results suggest that neither type of antigen exposure is superior for neutralising antibody durability. However, these results support vaccination to increase the durability and cross-neutralisation potential of neutralising responses, thereby enhancing protection against severe COVID-19. Funding: This work was supported by grants from The Capital Region of Denmark's Research Foundation, the Novo Nordisk Foundation, the Independent Research Fund Denmark, the Candys Foundation, and the Danish Agency for Science and Higher Education.
AB - Background: Given the importance of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the prevention of severe coronavirus disease 2019 (COVID-19), detailed long-term analyses of neutralising antibody responses are required to inform immunisation strategies. Methods: In this study, longitudinal neutralising antibody titres to an ancestral SARS-CoV-2 isolate and cross-neutralisation to delta and omicron isolates were analysed in individuals previously infected with SARS-CoV-2, vaccinated against COVID-19, or a complex mix thereof with up to two years of follow-up. Findings: Both infection-induced and vaccine-induced neutralising responses against SARS-CoV-2 appeared to follow similar decay patterns. Following vaccination in previously infected individuals, neutralising antibody responses were more durable than prior to vaccination. Further, this study shows that vaccination after infection, as well as booster vaccination, increases the cross-neutralising potential to both delta and omicron SARS-CoV-2 variants. Interpretation: Taken together, these results suggest that neither type of antigen exposure is superior for neutralising antibody durability. However, these results support vaccination to increase the durability and cross-neutralisation potential of neutralising responses, thereby enhancing protection against severe COVID-19. Funding: This work was supported by grants from The Capital Region of Denmark's Research Foundation, the Novo Nordisk Foundation, the Independent Research Fund Denmark, the Candys Foundation, and the Danish Agency for Science and Higher Education.
KW - COVID-19
KW - Cross-neutralisation
KW - Delta
KW - Longitudinal
KW - Neutralising antibody
KW - Omicron
KW - SARS-CoV-2
KW - Virus isolate
U2 - 10.1016/j.ebiom.2023.104475
DO - 10.1016/j.ebiom.2023.104475
M3 - Journal article
C2 - 36870117
AN - SCOPUS:85149279172
VL - 89
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 104475
ER -